Fact CheckerSign in

NCT07132671Not yet recruiting

MRI-guided Brachytherapy and Salvage SBRT Program

MRI-guided Brachytherapy + Salvage SBRT Program for Patients With Prostate Bed Relapses After Radical Prostatectomy

Source: ClinicalTrials.gov · Last updated 20 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Brachytherapy followed by MRI-guided irradiation has the potential to improve treatment results in patients with local relapses after radical prostatectomy

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
29 (estimated)
First submitted
17 Jun 2025
Start date
1 Oct 2025
Primary completion date
30 Jun 2030
Lead sponsor
Clinica Universidad de Navarra, Universidad de Navarra
NCT number
NCT07132671

What you commit to

  • Study type: Interventional
  • Planned participants: 29
  • From 1 Oct 2025 to the primary completion date, 30 Jun 2030
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Criteria the registry did not label

  • Patients with increasing PSA after RP and clinical evidence of PET PSMA/Choline+ and RMN+ isolated prostatic bed relapse (IPBR) that is implantable via transperineal route . The IPBR should be visible on TRUS imaging to allow proper implant placement.
  • Pathological confirmation is advised in all cases but it is not mandatory .
  • Patients with any of the following were not considered eligible:
    • Distance \< 5mm from the edge of the IPBR to any of the defined OARs (UV anastomosis, rectal wall, bladder wall, external urinary sphincter)
    • Distant Metastases
    • Isolated nodal relapses
    • Prior Irradiation to the IPBR area
    • Multicentric IPBRs
    • Life expectancy of less than 5 years or inability to tolerate and comply with an HDR procedure
  • No prior radiation therapy to the target areas;
  • Karnofsky performance status \> 70 with medical condition not contraindicating treatment with radical intent including maximal TURBT and concomitant chemotherapy;
  • WBC equal or greater than 3500 mm3; platelet count equal or greater than 135000 mm3; hemoglobin equal or greater than 10 gr/L; BUN equal or less than 20; serum creatinine equal or less than 2.0.
  • Ability to undergo MRI scanning.

Age in the registry: 18 years to 80 years · Sex: Male · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.